Managing Thyroid Disorders
Guides thyroid evaluation with TSH interpretation, medication titration, and nodule workup protocols.
Why This Skill Exists
Thyroid disorders are among the most common endocrine conditions encountered in primary care. Hypothyroidism affects 4.6% of the U.S. population (10.4 million), while hyperthyroidism affects approximately 1.2%. Thyroid nodules are found incidentally in up to 68% of adults on ultrasound, yet only 5-15% are malignant. The ATA (American Thyroid Association) 2015 guidelines for thyroid nodules, the ATA 2012 hypothyroidism guidelines, and the 2016 ATA hyperthyroidism guidelines provide the frameworks for management.
Common primary care challenges include over-treating subclinical hypothyroidism, misinterpreting TSH in the context of illness or medication effects, inappropriate thyroid ultrasound ordering, and failing to risk-stratify thyroid nodules. This skill provides structured protocols for TSH interpretation, levothyroxine titration, thyroid nodule workup, and referral criteria to ensure efficient, evidence-based thyroid management.
Checkpoint A: Pre-Draft Intake (Mandatory)
- What is the presenting concern (abnormal TSH, thyroid nodule, symptoms, medication adjustment)? Default: [REQUIRED]
- What is the most recent TSH and when was it drawn? Default: [REQUIRED]
- Is free T4 available? Free T3? Default: pending if TSH abnormal
- Is the patient currently on levothyroxine or antithyroid medication? Dose and duration? Default: none
- Are there thyroid antibodies on file (TPO, TRAb/TSI)? Default: not checked
- Has a thyroid ultrasound been performed? Results? Default: not done
- Is the patient pregnant, planning pregnancy, or postpartum? Default: no
- What medications or supplements may affect thyroid function or absorption (biotin, iron, calcium, PPI, estrogen)? Default: per med list
Documents to Request
- TSH trend (minimum 2-3 values over 6-12 months)
- Free T4 and T3 if available
- Thyroid antibodies (TPO antibodies, thyroglobulin antibodies, TSI/TRAb)
- Thyroid ultrasound report with TI-RADS classification if nodule present
- FNA cytopathology report (Bethesda classification) if biopsy performed
- Nuclear thyroid scan (I-123 uptake) if hyperthyroidism evaluation
- Current medication list highlighting levothyroxine dose and timing
- Supplements containing biotin (interferes with thyroid immunoassays)
- Pregnancy status and estimated gestational age if applicable
Step 1: TSH Interpretation Framework
| TSH (mIU/L) |
Free T4 |
Diagnosis |
Initial Action |
| 0.4-4.0 |
Normal |
Euthyroid |
No treatment; recheck if symptomatic |
| 4.0-10.0 |
Normal |
Subclinical hypothyroidism |
Repeat in 6-12 weeks; check TPO antibodies |
| >10.0 |
Normal or low |
Overt hypothyroidism |
Start levothyroxine |
| >4.0 |
Low |
Overt hypothyroidism |
Start levothyroxine |
| <0.4 |
Normal |
Subclinical hyperthyroidism |
Repeat in 6-12 weeks; evaluate if persistent |
| <0.1 |
Normal or high |
Overt hyperthyroidism |
Check T3, TSI/TRAb; refer endocrinology |
| Low |
Low |
Central hypothyroidism |
Pituitary evaluation; MRI; endocrinology referral |
Factors affecting TSH interpretation:
- Biotin supplementation: falsely low TSH and falsely high T4 on some assays; hold biotin 48-72 hours before testing
- Acute illness (sick euthyroid / non-thyroidal illness): low T3, variable TSH; recheck 6-8 weeks after recovery
- Pregnancy: TSH lower in first trimester (normal range: 0.1-2.5 in T1; 0.2-3.0 in T2/T3 per ATA)
- Medications: amiodarone (hypo or hyper), lithium (hypothyroidism), dopamine (suppresses TSH), high-dose glucocorticoids (suppresses TSH)
Step 2: Hypothyroidism Management
Levothyroxine dosing:
- Full replacement: 1.6 mcg/kg/day (ideal body weight)
- Starting dose in young, healthy adults: 1.6 mcg/kg/day
- Starting dose in elderly or cardiac disease: 25-50 mcg/day; increase by 12.5-25 mcg every 6-8 weeks
- Typical doses: 50-200 mcg/day for most adults
Administration instructions (critical for absorption):
- Take on empty stomach, 30-60 minutes before breakfast OR at bedtime (≥3 hours after dinner)
- Separate from calcium, iron, PPI, and soy by ≥4 hours
- Take consistently (same time, same conditions daily)
- Brand vs. generic: either acceptable, but avoid switching between brands/generics without rechecking TSH
Monitoring:
| Phase |
TSH Recheck Interval |
Target TSH |
| Initial titration |
Every 6-8 weeks until at goal |
0.5-2.5 mIU/L for most adults |
| Stable dose achieved |
Every 6-12 months |
0.5-2.5 mIU/L |
| Dose changed or new interfering medication |
6-8 weeks after change |
Per target |
| Pregnancy |
Every 4 weeks through week 20; then at 24 and 30 weeks |
Per trimester-specific range; <2.5 in first trimester |
| Elderly (>70 years) |
Every 6-12 months |
1.0-5.0 mIU/L acceptable; avoid over-treatment |
Subclinical hypothyroidism treatment decision:
- TSH >10: treat regardless of symptoms
- TSH 4.0-10.0 with symptoms + positive TPO: reasonable to treat
- TSH 4.0-10.0, asymptomatic, TPO negative: observe with repeat TSH in 6-12 months
- Pregnancy or planning pregnancy with TSH >2.5: treat per ATA
Step 3: Hyperthyroidism Evaluation
Workup when TSH is suppressed (<0.4):
- Confirm with repeat TSH + free T4 + total T3
- Check TSI or TRAb (Graves disease marker)
- If etiology unclear: radioactive iodine uptake (RAIU) scan
- Diffusely increased uptake → Graves disease
- Focal uptake → Toxic adenoma or toxic multinodular goiter
- Low/absent uptake → Thyroiditis (subacute, postpartum, medication-induced), exogenous thyroid hormone
Management (primary care role is diagnosis and referral):
- Symptomatic relief: propranolol 10-40mg TID (or atenolol 25-50mg daily) for tachycardia, tremor, anxiety
- Refer to endocrinology for definitive treatment decisions (antithyroid drugs, RAI, surgery)
- Methimazole preferred over PTU (except first trimester pregnancy); PTU used in thyroid storm
- Monitor for agranulocytosis on thionamides: WBC if fever/sore throat; educate patient to seek emergency care
Step 4: Thyroid Nodule Evaluation
ATA risk stratification using ultrasound features (TI-RADS):
| TI-RADS Category |
Suspicion |
FNA Threshold |
Features |
| TR1 |
Benign |
No FNA needed |
Simple cyst, purely cystic |
| TR2 |
Not suspicious |
No FNA needed |
Spongiform, mixed cystic/solid without suspicious features |
| TR3 |
Mildly suspicious |
FNA if ≥2.5 cm; follow if ≥1.5 cm |
Isoechoic/hyperechoic solid without suspicious features |
| TR4 |
Moderately suspicious |
FNA if ≥1.5 cm; follow if ≥1.0 cm |
Hypoechoic solid with 1 suspicious feature |
| TR5 |
Highly suspicious |
FNA if ≥1.0 cm; follow if ≥0.5 cm |
Hypoechoic + ≥2 suspicious features (microcalcifications, irregular margins, taller-than-wide, rim calcification, ETE) |
Bethesda cytopathology classification:
| Bethesda |
Diagnosis |
Risk of Malignancy |
Typical Action |
| I |
Non-diagnostic |
5-10% |
Repeat FNA in 4-6 weeks |
| II |
Benign |
0-3% |
Follow-up ultrasound in 12-24 months |
| III |
AUS/FLUS |
10-30% |
Repeat FNA or molecular testing (Afirma, ThyroSeq) |
| IV |
Follicular neoplasm |
25-40% |
Molecular testing or diagnostic lobectomy |
| V |
Suspicious for malignancy |
50-75% |
Surgery (lobectomy or thyroidectomy) |
| VI |
Malignant |
97-99% |
Surgery; extent based on tumor characteristics |
Step 5: Special Populations
Pregnancy:
- TSH target: trimester-specific (<2.5 first trimester recommended by ATA)
- Increase levothyroxine by 25-30% as soon as pregnancy confirmed
- Check TSH every 4 weeks through week 20
- TPO-positive women at higher risk for postpartum thyroiditis
Elderly (>65 years):
- TSH target less aggressive (1.0-5.0 acceptable per individual risk)
- Over-treatment causes atrial fibrillation, osteoporosis, and falls
- Start levothyroxine at low dose (25-50 mcg); titrate slowly
Amiodarone-induced thyroid dysfunction:
- Type 1: iodine-induced hyperthyroidism (underlying thyroid disease)
- Type 2: destructive thyroiditis (no underlying disease)
- Both require endocrinology consultation
Checkpoint B: Post-Draft Alignment (Mandatory)
- Is the TSH interpretation placed in clinical context (medications, pregnancy, illness)?
- Is the levothyroxine dose appropriate for the patient's weight, age, and cardiac status?
- Has thyroid nodule been risk-stratified using TI-RADS with appropriate FNA decision?
- Are monitoring intervals specified for the current management phase?
- Has endocrinology referral been considered for complex cases (hyperthyroidism, nodules, pregnancy)?
Quality Audit
Guidelines
- Never order thyroid ultrasound for abnormal TSH alone; ultrasound is indicated for palpable nodules, incidental imaging findings, or risk stratification of known nodules—not for screening
- Subclinical hypothyroidism (TSH 4-10, normal FT4) does NOT always require treatment; over-treatment in the elderly causes atrial fibrillation and osteoporosis
- Biotin (vitamin B7) at doses >5mg/day causes false TSH results on many immunoassays; always ask about biotin supplements before interpreting thyroid labs
- T3 (liothyronine) supplementation is not recommended by ATA for routine hypothyroidism management; evidence for combination T4/T3 therapy is insufficient
- Levothyroxine is the fourth most prescribed medication in the U.S.; dose changes of 12.5-25 mcg are clinically significant and require TSH rechecking
- Incidental thyroid nodules on CT, MRI, or PET require ultrasound follow-up; PET-avid nodules have a malignancy risk of approximately 35% and warrant FNA regardless of size
- Never stop antithyroid medications abruptly without endocrinology guidance; Graves disease relapse occurs in 50-60% after a standard 12-18 month course
- Postpartum thyroiditis (occurring in 5-10% of women, higher in TPO-positive) typically presents as transient hyperthyroidism followed by hypothyroidism; monitor closely for permanent hypothyroidism
1---2name: managing-thyroid-disorders3description: Guides thyroid evaluation with TSH interpretation, medication titration, and nodule workup protocols. Use when managing hypothyroidism, evaluating thyroid nodules, or adjusting levothyroxine.4---5
6# Managing Thyroid Disorders
7
8Guides thyroid evaluation with TSH interpretation, medication titration, and nodule workup protocols.
9
10## Why This Skill Exists
11
12Thyroid disorders are among the most common endocrine conditions encountered in primary care. Hypothyroidism affects 4.6% of the U.S. population (10.4 million), while hyperthyroidism affects approximately 1.2%. Thyroid nodules are found incidentally in up to 68% of adults on ultrasound, yet only 5-15% are malignant. The ATA (American Thyroid Association) 2015 guidelines for thyroid nodules, the ATA 2012 hypothyroidism guidelines, and the 2016 ATA hyperthyroidism guidelines provide the frameworks for management.
13
14Common primary care challenges include over-treating subclinical hypothyroidism, misinterpreting TSH in the context of illness or medication effects, inappropriate thyroid ultrasound ordering, and failing to risk-stratify thyroid nodules. This skill provides structured protocols for TSH interpretation, levothyroxine titration, thyroid nodule workup, and referral criteria to ensure efficient, evidence-based thyroid management.
15
16---
17
18## Checkpoint A: Pre-Draft Intake (Mandatory)
19
201. What is the presenting concern (abnormal TSH, thyroid nodule, symptoms, medication adjustment)? **Default: [REQUIRED]**
212. What is the most recent TSH and when was it drawn? **Default: [REQUIRED]**
223. Is free T4 available? Free T3? **Default: pending if TSH abnormal**
234. Is the patient currently on levothyroxine or antithyroid medication? Dose and duration? **Default: none**
245. Are there thyroid antibodies on file (TPO, TRAb/TSI)? **Default: not checked**
256. Has a thyroid ultrasound been performed? Results? **Default: not done**
267. Is the patient pregnant, planning pregnancy, or postpartum? **Default: no**
278. What medications or supplements may affect thyroid function or absorption (biotin, iron, calcium, PPI, estrogen)? **Default: per med list**
28
29### Documents to Request
30
31- TSH trend (minimum 2-3 values over 6-12 months)
32- Free T4 and T3 if available
33- Thyroid antibodies (TPO antibodies, thyroglobulin antibodies, TSI/TRAb)
34- Thyroid ultrasound report with TI-RADS classification if nodule present
35- FNA cytopathology report (Bethesda classification) if biopsy performed
36- Nuclear thyroid scan (I-123 uptake) if hyperthyroidism evaluation
37- Current medication list highlighting levothyroxine dose and timing
38- Supplements containing biotin (interferes with thyroid immunoassays)
39- Pregnancy status and estimated gestational age if applicable
40
41---
42
43## Step 1: TSH Interpretation Framework
44
45| TSH (mIU/L) | Free T4 | Diagnosis | Initial Action |
46|---|---|---|---|
47| 0.4-4.0 | Normal | Euthyroid | No treatment; recheck if symptomatic |
48| 4.0-10.0 | Normal | Subclinical hypothyroidism | Repeat in 6-12 weeks; check TPO antibodies |
49| >10.0 | Normal or low | Overt hypothyroidism | Start levothyroxine |
50| >4.0 | Low | Overt hypothyroidism | Start levothyroxine |
51| <0.4 | Normal | Subclinical hyperthyroidism | Repeat in 6-12 weeks; evaluate if persistent |
52| <0.1 | Normal or high | Overt hyperthyroidism | Check T3, TSI/TRAb; refer endocrinology |
53| Low | Low | Central hypothyroidism | Pituitary evaluation; MRI; endocrinology referral |
54
55**Factors affecting TSH interpretation:**
56- Biotin supplementation: falsely low TSH and falsely high T4 on some assays; hold biotin 48-72 hours before testing
57- Acute illness (sick euthyroid / non-thyroidal illness): low T3, variable TSH; recheck 6-8 weeks after recovery
58- Pregnancy: TSH lower in first trimester (normal range: 0.1-2.5 in T1; 0.2-3.0 in T2/T3 per ATA)
59- Medications: amiodarone (hypo or hyper), lithium (hypothyroidism), dopamine (suppresses TSH), high-dose glucocorticoids (suppresses TSH)
60
61---
62
63## Step 2: Hypothyroidism Management
64
65**Levothyroxine dosing:**
66- Full replacement: 1.6 mcg/kg/day (ideal body weight)
67- Starting dose in young, healthy adults: 1.6 mcg/kg/day
68- Starting dose in elderly or cardiac disease: 25-50 mcg/day; increase by 12.5-25 mcg every 6-8 weeks
69- Typical doses: 50-200 mcg/day for most adults
70
71**Administration instructions** (critical for absorption):
72- Take on empty stomach, 30-60 minutes before breakfast OR at bedtime (≥3 hours after dinner)
73- Separate from calcium, iron, PPI, and soy by ≥4 hours
74- Take consistently (same time, same conditions daily)
75- Brand vs. generic: either acceptable, but avoid switching between brands/generics without rechecking TSH
76
77**Monitoring:**
78
79| Phase | TSH Recheck Interval | Target TSH |
80|---|---|---|
81| Initial titration | Every 6-8 weeks until at goal | 0.5-2.5 mIU/L for most adults |
82| Stable dose achieved | Every 6-12 months | 0.5-2.5 mIU/L |
83| Dose changed or new interfering medication | 6-8 weeks after change | Per target |
84| Pregnancy | Every 4 weeks through week 20; then at 24 and 30 weeks | Per trimester-specific range; <2.5 in first trimester |
85| Elderly (>70 years) | Every 6-12 months | 1.0-5.0 mIU/L acceptable; avoid over-treatment |
86
87**Subclinical hypothyroidism treatment decision:**
88- TSH >10: treat regardless of symptoms
89- TSH 4.0-10.0 with symptoms + positive TPO: reasonable to treat
90- TSH 4.0-10.0, asymptomatic, TPO negative: observe with repeat TSH in 6-12 months
91- Pregnancy or planning pregnancy with TSH >2.5: treat per ATA
92
93---
94
95## Step 3: Hyperthyroidism Evaluation
96
97**Workup when TSH is suppressed (<0.4):**
981. Confirm with repeat TSH + free T4 + total T3
992. Check TSI or TRAb (Graves disease marker)
1003. If etiology unclear: radioactive iodine uptake (RAIU) scan
101 - Diffusely increased uptake → Graves disease
102 - Focal uptake → Toxic adenoma or toxic multinodular goiter
103 - Low/absent uptake → Thyroiditis (subacute, postpartum, medication-induced), exogenous thyroid hormone
104
105**Management (primary care role is diagnosis and referral):**
106- Symptomatic relief: propranolol 10-40mg TID (or atenolol 25-50mg daily) for tachycardia, tremor, anxiety
107- Refer to endocrinology for definitive treatment decisions (antithyroid drugs, RAI, surgery)
108- Methimazole preferred over PTU (except first trimester pregnancy); PTU used in thyroid storm
109- Monitor for agranulocytosis on thionamides: WBC if fever/sore throat; educate patient to seek emergency care
110
111---
112
113## Step 4: Thyroid Nodule Evaluation
114
115**ATA risk stratification using ultrasound features (TI-RADS):**
116
117| TI-RADS Category | Suspicion | FNA Threshold | Features |
118|---|---|---|---|
119| TR1 | Benign | No FNA needed | Simple cyst, purely cystic |
120| TR2 | Not suspicious | No FNA needed | Spongiform, mixed cystic/solid without suspicious features |
121| TR3 | Mildly suspicious | FNA if ≥2.5 cm; follow if ≥1.5 cm | Isoechoic/hyperechoic solid without suspicious features |
122| TR4 | Moderately suspicious | FNA if ≥1.5 cm; follow if ≥1.0 cm | Hypoechoic solid with 1 suspicious feature |
123| TR5 | Highly suspicious | FNA if ≥1.0 cm; follow if ≥0.5 cm | Hypoechoic + ≥2 suspicious features (microcalcifications, irregular margins, taller-than-wide, rim calcification, ETE) |
124
125**Bethesda cytopathology classification:**
126
127| Bethesda | Diagnosis | Risk of Malignancy | Typical Action |
128|---|---|---|---|
129| I | Non-diagnostic | 5-10% | Repeat FNA in 4-6 weeks |
130| II | Benign | 0-3% | Follow-up ultrasound in 12-24 months |
131| III | AUS/FLUS | 10-30% | Repeat FNA or molecular testing (Afirma, ThyroSeq) |
132| IV | Follicular neoplasm | 25-40% | Molecular testing or diagnostic lobectomy |
133| V | Suspicious for malignancy | 50-75% | Surgery (lobectomy or thyroidectomy) |
134| VI | Malignant | 97-99% | Surgery; extent based on tumor characteristics |
135
136---
137
138## Step 5: Special Populations
139
140**Pregnancy:**
141- TSH target: trimester-specific (<2.5 first trimester recommended by ATA)
142- Increase levothyroxine by 25-30% as soon as pregnancy confirmed
143- Check TSH every 4 weeks through week 20
144- TPO-positive women at higher risk for postpartum thyroiditis
145
146**Elderly (>65 years):**
147- TSH target less aggressive (1.0-5.0 acceptable per individual risk)
148- Over-treatment causes atrial fibrillation, osteoporosis, and falls
149- Start levothyroxine at low dose (25-50 mcg); titrate slowly
150
151**Amiodarone-induced thyroid dysfunction:**
152- Type 1: iodine-induced hyperthyroidism (underlying thyroid disease)
153- Type 2: destructive thyroiditis (no underlying disease)
154- Both require endocrinology consultation
155
156---
157
158## Checkpoint B: Post-Draft Alignment (Mandatory)
159
1601. Is the TSH interpretation placed in clinical context (medications, pregnancy, illness)?
1612. Is the levothyroxine dose appropriate for the patient's weight, age, and cardiac status?
1623. Has thyroid nodule been risk-stratified using TI-RADS with appropriate FNA decision?
1634. Are monitoring intervals specified for the current management phase?
1645. Has endocrinology referral been considered for complex cases (hyperthyroidism, nodules, pregnancy)?
165
166---
167
168## Quality Audit
169
170- [ ] TSH interpretation accounts for interfering factors (biotin, illness, pregnancy, medications)
171- [ ] Free T4 ordered when TSH is abnormal (not just TSH alone)
172- [ ] TPO antibodies checked for subclinical hypothyroidism to predict progression
173- [ ] Levothyroxine dose calculated per body weight or started conservatively if elderly/cardiac
174- [ ] Administration instructions documented (empty stomach, separation from interfering agents)
175- [ ] Monitoring interval appropriate (6-8 weeks during titration; 6-12 months when stable)
176- [ ] Subclinical hypothyroidism treatment decision documented with rationale
177- [ ] Thyroid nodule evaluated with ultrasound using TI-RADS before FNA decision
178- [ ] FNA threshold applied correctly based on TI-RADS category and size
179- [ ] Bethesda result documented with appropriate follow-up plan
180- [ ] Hyperthyroidism workup includes TSI/TRAb and consideration of RAIU scan
181- [ ] Pregnancy-specific TSH targets applied with appropriate dose adjustment
182- [ ] Endocrinology referral triggered for hyperthyroidism, Bethesda III+, pregnancy complications, or amiodarone-induced disease
183- [ ] Thyroid cancer surveillance plan documented if post-thyroidectomy
184
185---
186
187## Guidelines
188
189- Never order thyroid ultrasound for abnormal TSH alone; ultrasound is indicated for palpable nodules, incidental imaging findings, or risk stratification of known nodules—not for screening
190- Subclinical hypothyroidism (TSH 4-10, normal FT4) does NOT always require treatment; over-treatment in the elderly causes atrial fibrillation and osteoporosis
191- Biotin (vitamin B7) at doses >5mg/day causes false TSH results on many immunoassays; always ask about biotin supplements before interpreting thyroid labs
192- T3 (liothyronine) supplementation is not recommended by ATA for routine hypothyroidism management; evidence for combination T4/T3 therapy is insufficient
193- Levothyroxine is the fourth most prescribed medication in the U.S.; dose changes of 12.5-25 mcg are clinically significant and require TSH rechecking
194- Incidental thyroid nodules on CT, MRI, or PET require ultrasound follow-up; PET-avid nodules have a malignancy risk of approximately 35% and warrant FNA regardless of size
195- Never stop antithyroid medications abruptly without endocrinology guidance; Graves disease relapse occurs in 50-60% after a standard 12-18 month course
196- Postpartum thyroiditis (occurring in 5-10% of women, higher in TPO-positive) typically presents as transient hyperthyroidism followed by hypothyroidism; monitor closely for permanent hypothyroidism
CaseMark